Nothing Special   »   [go: up one dir, main page]

SG11201806120WA - Ror1 antibody compositions and related methods - Google Patents

Ror1 antibody compositions and related methods

Info

Publication number
SG11201806120WA
SG11201806120WA SG11201806120WA SG11201806120WA SG11201806120WA SG 11201806120W A SG11201806120W A SG 11201806120WA SG 11201806120W A SG11201806120W A SG 11201806120WA SG 11201806120W A SG11201806120W A SG 11201806120WA SG 11201806120W A SG11201806120W A SG 11201806120WA
Authority
SG
Singapore
Prior art keywords
international
antibody
ror1
pct
related methods
Prior art date
Application number
SG11201806120WA
Inventor
Christoph Rader
Haiyong Peng
Roger Beerli
Lorenz Waldmeier
Ulf Grawunder
Original Assignee
Scripps Research Inst
Nbe Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Nbe Therapeutics Ag filed Critical Scripps Research Inst
Publication of SG11201806120WA publication Critical patent/SG11201806120WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011101011111110110011111111101111011111 International Bureau ... .1 j ..... .....1 (10) International Publication Number (43) International Publication Date WO 2017/127664 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 14/725 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/014311 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 20 January 2017 (20.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/280,843 20 January 2016 (20.01.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: THE SCRIPPS RESEARCH INSTITUTE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 10550 North Torrey Pines Road, La Jolla, CA TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 92037 (US). NBE-THERAPEUTICS AG [CH/CH]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Hochbergerstr, 60c, CH-4057 Basel (CH). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: RADER, Christoph; 144 Victorian Lane, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Jupiter, FL 33458 (US). PENG, Haiyong; 1200 Town SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Center, #312, Jupiter, FL 33458 (US). BEERLI, Roger; GW, KM, ML, MR, NE, SN, TD, TG). Rebrainstrasse 34, CH-8106 Adlikon (CH). WALDMEI- Published: ER, Lorenz; Peter-rot-strasse 74, CH-4058 Basel (CH). — with international search report (Art. 21(3)) GRAWUNDER, Ulf; Weidweg 1, CH-4423 Hersberg — with sequence listing of description (Rule 5.2(a)) (CH). part (74) Agents: FITTING, Thomas et al.; The Scripps Research Institute, 10550 North Torrey Pines Road, Tpc-8, La Jolla, CA 92037 (US). (54) Title: ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS ROR1 mobs Vr F1 CDR: Paz CDA2 SR3 CDR3 PR4 21 tit 88 90 10' ' ,14SMICM21,1 Ma: 324 iTLIlagTHR: GIMIK 141 -71 (7M1 *MC Lai245gM1ll4 Fmcantul, 11M-111E40 DIragTHMI ?.T1144 gi111S1DST 1.h M AS Mf. , Hmr. IMMIT1IIVIA FOMMIF VI, CORI CDR3 FRI 23 98 107 'X961.-4D1 — 'Sal -Aux [MIMS. WHAM, PI:kit -01PM. M1-301 Mg 30C MI MI vl MAK ' IlitTC G • ERNI me ni_____... . EaRI oim: , 4 iSi1 GOROM.414. .IMM, 4•GL.Ln - — MU 1OH4 51M1LUMMOMM GMMICMI— 1191MOLARILI WISCV. , -- ' Alrft: '' IT PH PR2 CP.2 MI -402 Il Elik1-30' .4 1211i1-3 Ml. 7r IN el 1-1 FIG. 1 IN 1-1 (57) : ROR1 Antibody Compositions and Related Methods The disclosure provides antibodies, antibody drug conjugates, N antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chi- meric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the disclosure C are methods of using such antibodies in various diagnostic and therapeutic applications.
SG11201806120WA 2016-01-20 2017-01-20 Ror1 antibody compositions and related methods SG11201806120WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662280843P 2016-01-20 2016-01-20
PCT/US2017/014311 WO2017127664A1 (en) 2016-01-20 2017-01-20 Ror1 antibody compositions and related methods

Publications (1)

Publication Number Publication Date
SG11201806120WA true SG11201806120WA (en) 2018-08-30

Family

ID=57966152

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806120WA SG11201806120WA (en) 2016-01-20 2017-01-20 Ror1 antibody compositions and related methods

Country Status (16)

Country Link
US (3) US10618959B2 (en)
EP (1) EP3405496B1 (en)
JP (1) JP7000660B2 (en)
KR (1) KR20180101554A (en)
CN (1) CN108848669B (en)
AU (1) AU2017210327A1 (en)
BR (1) BR112018014615A2 (en)
CA (1) CA3011815A1 (en)
CL (1) CL2018001971A1 (en)
IL (1) IL260689B2 (en)
MX (1) MX2018008926A (en)
PH (1) PH12018501554A1 (en)
RU (1) RU2766190C2 (en)
SG (1) SG11201806120WA (en)
UA (1) UA125718C2 (en)
WO (1) WO2017127664A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368574A1 (en) 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-ror1 antibodies
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
WO2018197675A1 (en) * 2017-04-28 2018-11-01 Julius-Maximilians-Universität Würzburg Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
CA3067829A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
KR20230008269A (en) * 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 Antibody drug conjugates having high in vivo tolerability
JP7448903B2 (en) * 2017-11-03 2024-03-13 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating cancer by anti-ROR1 immunotherapy
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
WO2020127367A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
AU2019407814A1 (en) 2018-12-21 2021-07-22 Boehringer Ingelheim International Gmbh Bifunctional anti-PD-1/IL-7 molecule
BR112021012040A2 (en) 2018-12-21 2021-11-03 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
EP3897845A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional molecule directed against human pd-1
CN113677365A (en) * 2019-01-22 2021-11-19 瑞伟生物科技公司(美国) Novel anti-CD 40 antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN111286512A (en) * 2019-06-05 2020-06-16 南京艾德免疫治疗研究院有限公司 Chimeric antigen receptor targeting humanized tyrosine kinase orphan receptor 1 and uses thereof
KR20210028544A (en) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
US20220356246A1 (en) * 2019-09-27 2022-11-10 Nanjing Immunophage Biotech Co.,Ltd. Anti-ROR1 antibodies and preparation method and uses thereof
GB202020154D0 (en) 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
CN116848136A (en) * 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 Complement C3 antigen binding proteins
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
EP4377359A1 (en) * 2021-09-12 2024-06-05 Immunorizon Ltd. Anti-ror1 antibodies and uses thereof
AU2022376953A1 (en) 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023183950A2 (en) * 2022-03-25 2023-09-28 Board Of Regents, The University Of Texas System Anti-ror1 antibody and chimeric antigen receptor and methods of use thereof
WO2024025343A1 (en) * 2022-07-26 2024-02-01 (주)에임드바이오 Anti-ror1 antibody and use thereof
TW202417054A (en) * 2022-08-11 2024-05-01 美商翰森生物有限責任公司 Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
AU2002335640A1 (en) 2001-08-17 2003-03-03 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DE60315023T2 (en) 2002-04-26 2008-04-03 Gilead Sciences, Inc., Foster City ENRICHMENT IN THE CELL TO PHOSPHONATE ANALOGUE OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS OF ITSELF
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20080318212A1 (en) 2004-04-06 2008-12-25 Wilson Cindy A Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer
EP1948680A4 (en) 2005-10-28 2010-01-13 Univ California Methods and compounds for lymphoma cell detection and isolation
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2007146957A2 (en) * 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
JP2010511382A (en) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Cancer-related protein kinase
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
KR100994996B1 (en) 2008-08-06 2010-11-18 한국과학기술연구원 Biomarkers for identification of exposure to phenanthrene and the method of identification using the same
RU2744176C2 (en) * 2008-12-19 2021-03-03 Макродженикс, Инк. Covalent diabodies and use thereof
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
AU2010315057B2 (en) 2009-11-05 2015-05-14 Sloan Kettering Institute For Cancer Research Catenae: serosal cancer stem cells
EP2509949B1 (en) 2009-12-07 2014-04-23 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP3219731A1 (en) * 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (en) * 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit / human ROR1 antibodies
KR101897307B1 (en) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. Process for the preparation of morpholinyl anthracycline derivatives
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP2649098B1 (en) 2010-12-10 2017-11-22 Kancera AB Antibodies against ror1 and their uses
CA2981662C (en) 2011-01-14 2019-02-05 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20130131139A1 (en) 2011-11-17 2013-05-23 Oregon Health & Science University Ror1 as a gene target in acute lymphoblastic leukemia
PT2692865E (en) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Transposition-mediated identification of specific binding or functional proteins
DK2884999T3 (en) 2012-08-20 2021-01-04 Seattle Childrens Hospital Dba Seattle Childrens Res Inst METHOD AND COMPOSITIONS FOR CELLULAR IMMUNTERAPHY
KR102134088B1 (en) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US10786532B2 (en) 2012-10-02 2020-09-29 Versiti Blood Research Institute Foundation, Inc. Method of providing cellular therapy using modified natural killer cells or T lymphocytes
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2015113110A1 (en) 2014-01-29 2015-08-06 University Of Western Sydney A method for the purification of eye lens cells
JP2017513818A (en) 2014-03-15 2017-06-01 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors
SG10201808825XA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Defined composition gene modified t-cell products
LT3134095T (en) 2014-04-25 2020-06-10 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
KR102048855B1 (en) 2014-07-29 2019-11-26 셀렉티스 Ror1(ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
ES2850325T3 (en) 2014-10-09 2021-08-27 Engmab Sarl Bispecific antibodies against CD3epsilon and ROR1
JP2017536341A (en) 2014-10-09 2017-12-07 エンクマフ アーゲー Bispecific antibodies against CD3ε and ROR1 for use in the treatment of ovarian cancer
US10828352B2 (en) 2014-10-27 2020-11-10 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
US10690672B2 (en) 2014-12-08 2020-06-23 George Mason Research Foundation, Inc. Methods for breast cancer treatment
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
BR122020025870B1 (en) 2014-12-23 2024-01-09 Nbe-Therapeutics Ag METHOD FOR PRODUCING A DRUG-BINDING PROTEIN CONJUGATE
FR3030807B1 (en) 2014-12-23 2018-02-02 Thales NON-LINEAR METHOD OF ESTIMATING A MIXTURE OF SIGNALS
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
SI3280729T1 (en) 2015-04-08 2022-09-30 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
CN107709359A (en) 2015-04-24 2018-02-16 加利福尼亚大学董事会 The conditioning agent that ROR1 ROR2 are combined
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
JP2018521004A (en) 2015-05-18 2018-08-02 ユーリカ セラピューティックス， インコーポレイテッド Anti-ROR1 chimeric antigen receptor
UA126278C2 (en) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Cd3 binding polypeptides
EP3368574A1 (en) 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-ror1 antibodies
CN106918698B (en) 2015-12-25 2019-11-22 广州瑞博奥生物科技有限公司 A kind of phospho-AB chip agent box detecting human receptor tyrosine kinase enzyme
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
MA43658A (en) 2016-01-22 2018-11-28 Janssen Biotech Inc ANTI-MMR1 ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USE THEREOF
AU2017213844A1 (en) 2016-02-02 2018-08-02 Fred Hutchinson Cancer Center Anti-ROR1 antibodies and uses thereof
UY37127A (en) 2016-02-17 2017-08-31 Macrogenics Inc MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME

Also Published As

Publication number Publication date
US10618959B2 (en) 2020-04-14
EP3405496A1 (en) 2018-11-28
US20180340026A1 (en) 2018-11-29
US20220153839A1 (en) 2022-05-19
US20200299381A1 (en) 2020-09-24
UA125718C2 (en) 2022-05-25
RU2018129962A (en) 2020-02-20
PH12018501554A1 (en) 2019-05-20
IL260689B2 (en) 2023-04-01
CN108848669A (en) 2018-11-20
JP2019509021A (en) 2019-04-04
CN108848669B (en) 2022-06-07
US11242388B2 (en) 2022-02-08
CA3011815A1 (en) 2017-07-27
KR20180101554A (en) 2018-09-12
RU2018129962A3 (en) 2020-06-22
WO2017127664A1 (en) 2017-07-27
IL260689A (en) 2022-12-01
JP7000660B2 (en) 2022-02-04
EP3405496B1 (en) 2023-10-25
RU2766190C2 (en) 2022-02-09
CL2018001971A1 (en) 2018-12-21
BR112018014615A2 (en) 2018-12-11
MX2018008926A (en) 2019-01-10
AU2017210327A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
SG11201806120WA (en) Ror1 antibody compositions and related methods
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201810883TA (en) Combination therapy
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201808630WA (en) Humanized anti-pacap antibodies and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201810076WA (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
SG11201909656YA (en) Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function